Methodological issues in the epidemiological study of the teratogenicity of drugs

Congenital Anomalies

Volumn 45, Issue 2, 2005, Pages 44-51

  Källén, Bengt A J ^a  

^a UNIVERSITY OF LUND   (Sweden)

Author keywords

Bias; Congenital malformation; Drug; Epidemiology; Teratogenesis

Indexed keywords

ANALGESIC AGENT; ANTIASTHMATIC AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; CARBAMAZEPINE; CORTICOSTEROID; GESTAGEN; INSULIN; ISOTRETINOIN; LORATADINE; MECLOZINE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; THALIDOMIDE; VALPROIC ACID; TERATOGENIC AGENT;

BECKWITH WIEDEMANN SYNDROME; CLEFT FACE; CLINICAL TRIAL; COHORT ANALYSIS; DATA ANALYSIS; DIABETES MELLITUS; DRUG SURVEILLANCE PROGRAM; EPILEPSY; ESOPHAGUS ATRESIA; HEALTH INSURANCE; HUMAN; MATERNAL HYPERTENSION; MEDICAL RESEARCH; META ANALYSIS; PREMATURE LABOR; PRENATAL DIAGNOSIS; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SOCIAL STATUS; SPINA BIFIDA; SYSTEMATIC REVIEW; TERATOGENICITY; CONGENITAL MALFORMATION; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGY; FEMALE; INTERVIEW; NEWBORN; PREGNANCY; PRENATAL EXPOSURE; RECALL;

ABNORMALITIES, DRUG-INDUCED; BIAS (EPIDEMIOLOGY); COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; INFANT, NEWBORN; INTERVIEWS; MENTAL RECALL; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; TERATOGENS;

EID: 23844543814     PISSN: 09143505     EISSN: 17414520     Source Type: Journal    
DOI: 10.1111/j.1741-4520.2005.00062.x     Document Type: Review

References (59)

1. Åberg A, Westbom L, Källén B (2001) Congenital malformations among infants whose mothers had gestational diabetes or preexisting diabetes. Early Human Dev 61: 85-95.
2. Baroz Z, Moretti ME, Mareels G, van Tittelboom T, Koren G (1999) Reporting bias in retrospective ascertainment of drug-induced embryopathy. Lancet 354: 1700-1701.
3. Boneva RS, Moore CA, Botto L, Wong LY, Erickson JD (1999) Nausea during pregnancy and congenital heart defects: A population-based case-control study. Am J Epidemiol 149: 717-725.
4. Brent RR (1994) Cardiovascular birth defects and prenatal exposure to female sex hormones: Importance of utilizing proper epidemiological methods and teratologic principles. Teratology 49: 159-161.
5. Castilla EE, Orioli M (1983) [The collaborative Latino-American study of congenital malformations: ECLAMC/MONITOR]. Interciencia 8: 271-278. (In Spanish.).
6. Costei AM, Kozer E, Ho T, Ito S, Koren G (2002) Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 156: 1129-1132.
7. Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J (1999) A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. Reprod Toxicol 13: 531-536.
8. Dansky L, Andermann E, Andermann F (1982) Marriage and fertility in epileptic patients. Epilepsia 21: 261-271.
9. Dean JCS, Hailey H, Moore SJ, Lloyd DJ, Turnpenny PD, Little J (2002) Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet 39: 251-259.
10. Dolovich LR, Addis A, Vaillancourt JMR, Power JDB, Koren G, Einarson TR (1998) Benzodiazepine use in pregnancy and major malformations or oral clefts: Meta-analysis of cohort and case-control studies. Br Med J 317: 839-843.
11. Ekelund H, Kullander S, Källén B (1970) Major and minor malformations in newborns and infants up to one year of age. Acta Paediat Scand 59: 297-302.
12. Ericson A, Källén B, Meirik O, Westerholm P (1982) Gastrointestinal atresia and maternal occupation during pregnancy. Occup Med 24: 515-518.
13. Feldman Y, Koren G, Mattice D, Shear H, Pellergrini E, MacLeod SM (1989) Determinants of recall and recall bias in studying drugs and chemical exposure in pregnancy. Teratology 40: 37-45.
14. Ferencz C, Correa-Villasenor A, Loffredo CA, Wilson PD (1997) Genetic and Environmental Risk factors of Major Cardiovascular Malformations: The Baltimore-Washington Infant Study: 1981-1989. Futura Publishing Co, Amonk, NY.
15. Fox AW, Chambers CD, Anderson PO, Diamond ML, Spierings ELH (2002) Evidence-based assessment of pregnancy outcome after sumatriptan exposure. Headache 42: 8-15.
16. Gregg NMcA (1941) Congenital cataract following German measles in the mother. Trans Ophthalmol Soc Aust 3: 35-45.
17. Heinonen OP, Slone D, Shapiro S (1977a) Birth Defects and Drugs In Pregnancy. Publishing Sciences Group, Inc., Littleton, Mass.
18. Heinonen OP, Slone D, Monson RR, Hook EB, Shapiro S (1977b) Cardiovascular birth defects and antenatal exposure to female sex hormones. New Engl J Med 296: 67-70.
19. Hendrick V, Smith LM, Suri R, Hwang S, Haynes D, Altshuler L (2003) Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 188: 812-815.
20. Hernández-Diaz S, Harnán MA, Meyer K, Werler MM, Mitchell AA (2003) Case-crossover and case-time-control designs in birth defects epidemiology. Am J Epidemiol 158: 385-391.
21. Johnson KA, Weber PA, Jones KL, Chambers CD (2001) Selection bias in teratology information service pregnancy outcome studies. Teratology 64: 79-82.
22. Källén B (1986) A register study of maternal epilepsy and delivery outcome with special reference to drug use. Acta Neurol Scand 73: 253-259.
23. Källén B (1989) A prospective study of some aetiological factors in limb reduction defects in Sweden. J Epidem Comm Health 43: 86-91.
24. Källén B (2004) Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 158: 312-316.
25. Källén B, Tandberg A (1983) Lithium and pregnancy. A cohort study of manic-depressive women. Acta Psychiatr Scand 68: 134-139.
26. Källén B, Lygner PE (2001) Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache 41: 351-356.
27. Källén B, Otterblad Olausson P (2001) Monitoring of maternal drug use and infant congenital malformations. Does loratadine cause hypospadias? Int J Risk Safety Med 14: 115-119.
28. Källén B, Mottet I (2003) Delivery outcome after the use of meclozine in early pregnancy. Eur J Epidem 18: 665-669.
29. Källén B, Castilla EE, Robert E et al. (1992) An international case-control study on hypospadias. The problem with variability and the beauty of diversity. Eur J Epidemiol 8: 256-263.
30. Källén B, Rydhstroem H, Åberg A (1999) Asthma during pregnancy - a population based study. Eur J Epidem 16: 167-171.
31. Källén BAJ, Carlsson SS, Bengtsson BKA (1995) Diabetes insipidus and use of desmopressin (Minirin) during pregnancy. Eur J Endocrin 132: 144-146.
32. Kullander S, Källén B (1976) A prospective study of drugs and pregnancy. I. Psychopharmaca. Acta Obstet Gynecol Scand 55: 25-33.
33. Lammer EJ, Chen DT, Hoar RM et al. (1985) Retinoic acid embryopathy. N Engl J Med 313: 837-841.
34. Lentz W (1961) [Child malformations after drug use during pregnancy?]. Dtsch Med Wochenschr 86: 2555-2556. (In German.).
35. Martínez-Frías ML, Salvador J, Prieto L, Zaplana J (1984) Epidemiological study of gastroschisis and omphalocele in Spain. Teratology 29: 377-382.
36. McBride WG (1961) Thalidomide and congenital abnormalities. Lancet 2: 1358.
37. McElhatton PR, Garbis HM, Elefant E et al. (1996) The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 10: 285-294.
38. Meadow SR (1968) Congenital abnormalities and anticonvulsant drugs. Proc Roy Soc Med 63: 12-49.
39. Mitchell AA, Rosenberg L, Shapiro S et al. (1981) Birth defects related to Bendectin use in pregnancy. JAMA 245: 2311-2314.
40. Mutchinick O, Lisker R, Babinsky V (1988) [the Mexican program of 'Registration and epidemiological surveillance of external congenital malformations']. Salud Publica Mex 30: 88-100. (In Spanish).
41. Myrianthopoulos NC (1985) Malformations in Children from One to Seven Years. A Report from the Collaborative Perinatal Project. Alan R. Liss, New York.
42. National Board of Health and Welfare (2003) Centre for Epidemiology. Research Report from EpC: The Swedish Medical Birth Registry - a summary of content and quality. Available at http://www.sos.se/FULLTEXT/112/2003-112-3/ 2003-112-3.pdf
43. Nielsen GL, Sørensen HT, Larsen H, Pedersen L (2001) Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal antiinflammatory drugs: Population based observational study and case-control study. Br Med J 322: 266-270.
44. Olesen C, Thrane N, Nielsen GL, Sørensen HT, Olsen J (2001) A population-based prescription study of asthma drugs during pregnancy: Changing the intensity of asthma therapy and perinatal outcomes. Respiration 68: 256-261.
45. Olshan AF, Faustman EM (1989) Nitrosatable drug exposure during pregnancy and adverse pregnancy outcome. Int J Epidemiol 18: 891-899.
46. Park-Wyllie L, Mazzotta P, Pastuszak A et al. (2000) Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. Teratology 62: 385-192.
47. Pradat PP, Robert-Gnansia E, Di Tanna GL et al. (2003) First trimester exposure to corticosteroids and oral clefts. Birth Defects Res Part A 67: 968-970.
48. Reiffeldridge R, Heffner CR, Ephross SA, Tennis PS, White AD, Andrews EB (2000) Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: A pharmaceutical company commitment. Am J Obstet Gynecol 182: 169-163.
49. Robert E, Guibaud P (1982) Maternal valproic acid and congenital neural tube defects. Lancet 2: 937.
50. Robert E, Francannet C, Robert JM (1988) [The congenital malformation register of the region Rhone-Alpes/Aurvergne. The interest and limits of teratovigilance. Eleven years experience (1976-1986).]. J Gynecol Obstet Biol Reprod 17: 601-607. (In French.).
51. Robert E, Vollset SE, Botto L et al. (1994) Malformation surveillance and maternal drug exposure: The MADRE project. Int J Risk Safety Med 6: 75-118.
52. Rosa F (1999) Databases in the assessment of the effects of drugs during pregnancy. J Allergy Clin Immunol 103: S360-361.
53. Sørensen HT, Steffensen FH, Olesen C, Nielsen GL, Pedersen L (1998) Pregnancy outcome in women exposed to calcium channel blockers. Reprod Toxicol 12: 383-384.
54. Torfs CP, Katz EA, Bateson TF, Lam PK, Curry CJR (1996) Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 54: 84-92.
55. Warkany J (1961) Environmental teratogenic factors. In: Fishbein M (ed) First International Conference on Congenital Malformations. Lippincott, Philadelphia and Montreal, pp 99-105.
56. Wen SW, Demissie KW, Liu S (2001) Adverse outcome in pregnancies of asthmatic women: Results from a Canadian population. Ann Epidemiol 11: 7-12.
57. Werler MM, Sheehan JE, Mitchell AA (2003) Association of vasoconstrictive exposures with risks of gastroschisis and small intestinal atresia. Epidemiology 14: 349-354.
58. Wiedemann H-R (1961) [Reference to an ongoing cluster of hypo- and aplastic malformations of the limbs]. Med Welt 37: 1863-1866. (In German.).
59. Wiseman RA, Dodds-Smith I (1984) Cardiovascular birth defects and antenatal exposure to female sex hormones. A reevaluation of some base data. Teratology 30: 359-370.